Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma

Diane-Charlotte Imbs 1, 2 Raouf El Cheikh 1, 2 Arnaud Boyer 3, 1, 2 Joseph Ciccolini 1, 2 Celine Mascaux 3, 2 Bruno Lacarelle 1, 2 Fabrice Barlesi 3, 2 Dominique Barbolosi 2, 1 Sébastien Benzekry 4, 5, *
* Auteur correspondant
1 SMARTc unit - Simulation & Modelling : Adaptive Response for Therapeutics in Cancer
2 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
3 Oncologie multidisciplinaire et innovations thérapeutiques [Hôpital Nord - APHM]
4 IMB - Institut de Mathématiques de Bordeaux
5 MONC - Modélisation Mathématique pour l'Oncologie
IMB - Institut de Mathématiques de Bordeaux, Inria Bordeaux - Sud-Ouest, Institut Bergonié - CRLCC Bordeaux
Abstract : Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced non-squamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC-bearing mice using. First, experiments demonstrated improved efficacy when using sequential versus concomitant scheduling of bevacizumab and chemotherapy. Using a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (70 vs. 74 days). Alternate sequencing of 8 days failed in achieving similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences.
Keywords : Population pharmacokinetics-pharmacodynamics Drug-drug interactions Pharmacokinetics-pharmacodynamics Computational biology Personalized Therapy Systems biology Mixed effect models Combination therapy Oncology
Type de document :
Article dans une revue
CPT: Pharmacometrics and Systems Pharmacology, American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics, 2018, pp.1-9. 〈10.1002/psp4.12265〉
Liste complète des métadonnées

Littérature citée [48 références]  Voir  Masquer  Télécharger
https://hal.inria.fr/hal-01624423
Contributeur : Sebastien Benzekry <>
Soumis le : vendredi 8 décembre 2017 - 19:09:20
Dernière modification le : lundi 27 août 2018 - 09:44:39

Fichier

Imbs_17_CPT_PSP_Revisiting Bev...
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

INSMI | BERGONIE | TDS-MACS | FNCLCC | IMB | UNIV-AMU | INRIA

Citation

Diane-Charlotte Imbs, Raouf El Cheikh, Arnaud Boyer, Joseph Ciccolini, Celine Mascaux, et al.. Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma. CPT: Pharmacometrics and Systems Pharmacology, American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics, 2018, pp.1-9. 〈10.1002/psp4.12265〉. 〈hal-01624423v2〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

301

Téléchargements de fichiers

45

Contact


archive-ouverte@inria.fr